Press Releases
Two Join Board of Directors of FibroGen, Inc.
San Francisco, California - May 25, 2010
FibroGen, Inc. announced today that Roberto Pedro Rosenkranz, Ph.D. and James A. Schoeneck have been appointed to the FibroGen Board of Directors. FibroGen has expanded the Board to include Dr. Rosenkranz and Mr. Schoeneck, who will not replace current Directors.
Dr. Rosenkranz is the chairman and Chief Executive Officer of ROXRO PHARMA, Inc. and is also a Director of Pherin Pharmaceuticals. Prior to his leadership of ROXRO, Dr. Rosenkranz was president and COO of Scios, Inc., and held multiple research, development and marketing posts at Syntex Laboratories, Inc., and Roche Laboratories. He has led multiple public policy efforts for both the United States and Mexican governments to address drug abuse in these nations.
Mr. Schoeneck is CEO and Director of BrainCells Inc. He is also a Director of Depomed, Inc. He previously served as CEO and Director of ActivX Biosciences, Inc., and as president, CEO and Director of Prometheus Laboratories, Inc. He also served as vice president and general manager of the Immunology Business Unit and vice president of Marketing and Commercial Development at the Johnson & Johnson subsidiary, Centocor, Inc., and in multiple sales and marketing positions at Rhone-Poulenc Rorer.
"We are pleased to welcome Roberto and Jim to our Board," said Thomas B. Neff, Chairman and CEO of FibroGen. "Their leadership experience in start-up and larger-scale biotech concerns as well as large pharmaceutical companies will bring additional hands-on commercial and development management experience at a dynamic time in FibroGen's development."
About FibroGen
FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, conditions associated with tissue damage or injury, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen's proprietary cosmetic dermal filler and biomaterials supply business.
For more information about FibroGen, Inc., please visit www.fibrogen.com.
Contact:
Laura Hansen, Ph.D., Director, Corporate Communications
415-978-1433 or lhansen@fibrogen.com
